Minerva Neurosciences (NERV) reported a loss of $0.18 per share in its second quarter, beating consensus forecast by 12 cents. The company ended the quarter with $88.7 million in cash and cash equivalents on its balance sheet.

Repligen (RGEN) reported earnings of $0.16 per share in its second quarter, beating consensus forecast by 3 cents. The company�s revenue for the quarter was $29.17 million, up 35.9% on a year-over-year basis. Revenue beat consensus forecast by $4.42 million.

Progenics Pharmaceuticals (PGNX) reported a loss of $0.08 per share in its second quarter, beating consensus forecast by 5 cents. The company reported revenue of $8.48 million, up 337.1% on a year-over-year basis. Revenue beat consensus forecast by $2.15 million.

Genocea Biosciences (GNCA) reported a loss of $0.39 per share in its second quarter, beating consensus forecast by 5 cents. The company�s cash balance at the end of the quarter stood at $86 million.

Ligand Pharmaceuticals (LGND) reported earnings of $0.50 per share in its second quarter, beating consensus forecast by 10 cents. The company reported revenue of $19.52 million, up 6% on a year-over-year basis. Revenue beat consensus forecast by $1.4 million.

Medgenics (MDGN) reported a loss of $0.35 per share in its second quarter, missing consensus forecast by 5 cents. The company ended the quarter with cash and cash equivalents of $53.7 million on its balance sheet.